Fibrinolysis Inhibition and Fibronectin in the Blood in Patients with the Delayed Microembolism Syndrome

References

• Arfors K-E., Busch C., Jacobsson S., Lindquist O., Malmberg P., Rammer L., Saldeen T. Pulmonary insufficiency following intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog. Acta Chir. Scand 1972; 138: 445–452
   PubMedGoogle Scholar
• Bagge L., Rammer L., Saldeen T. Experimental study of the importance of plasminogen activation inhibition for decreased elimination of intravascular fibrin after trauma. Forens Sci 1973; 2: 54–55
   Google Scholar
• Bagge L., Björk I., Saldeen T., Wallin R. Purification and characterization of an inhibitor of plasminogen activation from posttraumatic patients. Forens Sci 1976; 7: 83–86
   Google Scholar
• Bagge L., Björk I., Saldeen T., Wallin R. Purification of a fibrinolysis inhibitor in serum from posttraumatic patients. Thrombos Haemostas 1978; 39: 97–108
   PubMed Web of Science ®Google Scholar
• Bagge L., Saldeen T. The primary fibrinolysis inhibitor and trauma. Thrombos Res 1978; 13: 1131–1136
   PubMedGoogle Scholar
• Bagge L., Jacobsson H., Saldeen T. Posttraumatic variation of the primary fibrinolysis inhibitor (α2-antiplasmin). Progress in Chemical Fibrinolysis and Thrombolysis 5. Churchill Livingstone. 1981; 307–312
   Google Scholar
• Bagge L., Carlin G., Hjelmstedt Å., Högstorp H., Jacobsson H., Modig J., Saldeen T. Fibrinolysis inhibition after a major standardized trauma. Uppsala J Med Sci 1982; 87: 55–66
   PubMed Web of Science ®Google Scholar
• Bredenberg C. E., James P. M., Collins J., Andersson R. W., Martin A. M., Hardaway R. M. Respiratory failure in shock. Ann Surg 1969; 169: 392–403
   PubMed Web of Science ®Google Scholar
• Busch C., Dahlgren S., Jacobsson S., Jung B., Modig J., Saldeen T. The use of 125I-labelled fibrinogen for determination of fibrin trapping in the lungs in patients developing the microembolism syndrome. Acta Anaesth Scand, Suppl 1975; 57: 46–54
   Google Scholar
• Carlin G., Modig J., Saldeen T. Effect of infusion of dextran 70 on fibrinolysis inhibition activity of serum in man. Acta Chir Scand 1979; 145: 129–131
   Google Scholar
• Carlin G., Karlström G., Modig J., Saldeen T. Effect of dextran on fibrinolysis inhibition activity in the blood after major surgery. Acta Anaesth Scand 1980; 24: 375–378
   PubMed Web of Science ®Google Scholar
• Deutsch D. G., Mertz E. T. Plasminogen purification from human plasma by affinity chromatography. Science 1970; 170: 1095–1096
   PubMed Web of Science ®Google Scholar
• Engvall E., Rouslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer 1977; 20: 1–5
   PubMed Web of Science ®Google Scholar
• Hjelm H., Hjelm K., Sjöquist J. Protein A from Staphylococcus Aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett 1982; 28: 73–76
   Google Scholar
• Johansson S., Rubin K., Höök M., Ahlgren T., Seljelid R. In vitro biosynthesis of cold insoluble globulin (fibronectin) by mouse peritoneal macrophages. FEBS Lett 1979; 105: 313–316
   PubMed Web of Science ®Google Scholar
• Kluft C., Los P., Jie A. F. H. Assay and occurrence of the two forms of α2-antiplasmin in plasma. Thrombos Haemostas 1981; 46: 281
   Google Scholar
• Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Int J of Immunochemistry 1965; 2: 235–254
   PubMedGoogle Scholar
• Moroi M., Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956–5965
   PubMed Web of Science ®Google Scholar
• Mosher D. F., Williams E. M. Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation. J Lab Clin Med 1978; 91: 729–735
   PubMed Web of Science ®Google Scholar
• Paraskevas M., Nilsson I. M., Martinsson G. A method for determining serum inhibitors of plasminogen activation. Scand J Clin Invest 1962; 14: 138–144
   PubMed Web of Science ®Google Scholar
• Rubin K., Johansson S., Pettersson I., Ocklind C., Öbrink B., Höök M. Attachment of rat hepatocytes to collagen or fibronectin does not involve a collagen-fibronectin interaction. Biochem Biophys Res Commun 1979; 91: 86–94
   PubMed Web of Science ®Google Scholar
• Saba T. M., Blumenstock F. A., Scovill W. A., Bernard H. Cryoprecipitate reversal of opsonic α2-surface binding glycoprotein deficiency in septic surgical and trauma patients. Science 1978; 201: 622–624
   PubMed Web of Science ®Google Scholar
• Saldeen T. The microembolism syndrome. Microvasc Res 1976; 11: 227–259
   PubMedGoogle Scholar
• Saldeen T., Bagge L., Jacobsson H., Wallin R. Purification and characterization of a fibrinolysis inhibitor. Forens Sci 1977; 10: 149–151
   Google Scholar
• Scovill W. A., Saba T. M., Blumenstock F. A., Bernard H., Powers S. R., Jr. Opsonic α2-surface binding glycoprotein therapy during sepsis. Ann Surg 1978; 188: 521–529
   PubMed Web of Science ®Google Scholar
• Teger-Nilsson A-C., Friberger P., Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403–409
   PubMed Web of Science ®Google Scholar
• Wallin R., Bagge L., Saldeen T. Viewpoints on a clot lysis method for determination of fibrinolysis inhibition. Forens Sci 1977; 10: 154–156
   Google Scholar
• Wiman B., Collen D. Purification and characterisation of human antiplasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19–26
   PubMedGoogle Scholar